META-ANALYSIS OF PATIENTS (PTS) PREVIOUSLY TREATED WITH TAXANES FROM THREE RANDOMIZED TRIALS OF BEVACIZUMAB (BV) AND FIRST-LINE CHEMOTHERAPY AS TREATMENT FOR METASTATIC BREAST CANCER (MBC)

被引：0
|
作者：
Miles, D. W. [1 ]
Romieu, G. [2 ]
Dieras, V. [3 ]
Chen, D. [4 ]
Duenne, A. [5 ]
O'Shaughnessy, J. [6 ]
机构：
[1] Mt Vernon Canc Ctr, London, England
[2] CRLC Val Aurelle, Montpellier, France
[3] Inst Curie, Paris, France
[4] Genentech Inc, San Francisco, CA 94080 USA
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Baylor Sammons Canc Ctr, Dallas, TX USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：97 / 97
页数：1
相关论文
共 50 条
  • [21] Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study
    Pivot, X.
    Verma, S.
    Thomssen, C.
    Passos-Coelho, J. L.
    Latini, L.
    Ciruelos, E.
    Silva, M.
    von Moos, R.
    Chang, H.
    Miles, D. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Cisplatin-vinorelbine as first line chemotherapy in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes: Results of a retrospective analysis
    Raafat, J.
    Mourad, C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : S182 - S182
  • [23] Oral Vinorelbine in Combination With Capecitabine as a First Line Treatment in Patients (pts) With Metastatic Breast Cancer (MBC) Previously Treated With Anthracyclines ± Taxanes - Preliminary Results of a Multicentric Phase II Trial in Egypt
    Kandil, A.
    Hamada, E.
    Moawad, M.
    El Arab, L. Ezz
    Metwalli, H.
    Bathiouny, M.
    Mourad, C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S351 - S351
  • [24] Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer
    Hochster, Howard S.
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (05) : S8 - S14
  • [25] Magnitude of benefit of the addition of bevacizumab (BEVA) to first-line chemotherapy (CT) for advanced/metastatic colorectal cancer (MCRC): Meta-analysis of randomized clinical trials
    Vaccaro, V.
    Cuppone, F.
    Loupakis, F.
    Milella, M.
    Carlini, P.
    Nistico, C.
    Falcone, A.
    Terzoli, E.
    Cognetti, F.
    Bria, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] Polymorphisms interaction to predict bevacizumab (BV) efficacy in metastatic breast cancer (MBC) patients (pts): An exploratory retrospective analysis
    Coltelli, Luigi
    Fontana, Andrea
    Bocci, Guido
    Camerini, Andrea
    Ferro, Antonella
    Cazzaniga, Marina Elena
    Casadei, Virginia
    Pazzagli, Ilaria
    Marcucci, Lorenzo
    Allegrini, Giacomo
    Lucchesi, Sara
    Bona, Eleonora
    Scalese, Marco
    Orlandi, Paola
    Villa, Federica
    Morini, Silvano
    Amoroso, Domenico
    Arrighi, Giada
    Filidei, Mario
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Efficacy of first-line capecitabine plus bevacizumab in patients with ER/PgR-positive metastatic breast cancer (MBC) and those previously treated with hormone therapy
    Dieras, V.
    Semiglazov, V.
    Tjulandin, S.
    [J]. EJC SUPPLEMENTS, 2010, 8 (03): : 202 - 202
  • [28] Efficacy of adding an immune checkpoint inhibitor to chemotherapy in the first-line treatment of metastatic triple-negative breast cancer: A meta-analysis of randomized controlled trials
    Ergun, Y.
    Kalkan, Z.
    Ileri, S.
    Tunc, S.
    Urakci, Z.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S212 - S212
  • [29] Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis
    Baraniskin, Alexander
    Buchberger, Barbara
    Pox, Christian
    Graeven, Ulli
    Holch, Julian W.
    Schmiegel, Wolff
    Heinemann, Volker
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 106 : 37 - 44
  • [30] Impact of insulin resistance (IR) on the prognosis of metastatic breast cancer (MBC) patients treated with first-line chemotherapy (CT).
    Gennari, Alessandra
    Puntoni, Matteo
    Nanni, Oriana
    De Censi, Andrea
    Bruzzi, Paolo
    Paleari, Laura
    Freschi, Andrea
    Amaducci, Laura
    Bologna, Alessandra
    Gianni, Lorenzo
    Amadori, Dino
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345